Word, I still own a not insignificant quantity of BPTH shares (although it becomes less significant with every recent management decision). I have held my position for in excess of 5 years now having purchased shares at a variety of prices from $0.30 to just short of $5 pps. I feel a responsibility, as a shareholder, to not only get this technology to the market but to hold the management team accountable for their performance or lack of performance. I believe that once the therapy is available to treat the various targeted cancers the share price will not be an issue. Right now,IMO, we do not have the correct management to make that happen quickly and efficiently.
Market Data 
Markets 
AI
